TTY Biopharm Company Stock Forecast for 2023 - 2025 - 2030

Updated on 03/28/2024

Stock Rating
18
Price Target
NT$86.50
Consensus
Neutral
Upside
7.05%
Analysts
0
Stock Rating
18
Upside
7.05%
Analysts
0
Price Target
NT$86.50

TTY Biopharm Company Stock Forecast and Price Target

Given the average yearlong price target of NT$86.50 provided by prominent analysts over the past few months, there is a potential upside of approximately 7.05% from the last closing price in March, 2024 for TTY Biopharm Company's stock if it is reached. This estimation is based on a high estimate of NT$95.00 and a low estimate of NT$78.00. Even if you are not interested in 4105 stock, it is still crucial to be aware of its competitors.

NT$86.50

7.05% Upside

Hold
Hold

TTY Biopharm Company Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, TTY Biopharm Company's Price has decreased from NT$71.45 to NT$0.00 – a 100.00% drop! For next year, the 2 analysts predict Fair Value of NT$110.17, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is Fair Valueof NT$115.17, which would mean a seven-year growth forecast of 100.00%.

2024 Fair Value Forecast
NT$110.17
2025 Fair Value Forecast
NT$128.46
2026 Fair Value Forecast
NT$122.37
2027 Fair Value Forecast
NT$77.80
2028 Fair Value Forecast
NT$90.25
2029 Fair Value Forecast
NT$104.83
2030 Fair Value Forecast
NT$115.17
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 9
$161.23 Buy/Sell $174.55 5.44%
ABT Stock Forecast Abbott Laboratories Outperform 9
$120.19 Buy/Sell $118.92 4.83%
AZN Stock Forecast AstraZeneca PLC Outperform 17
£104.50 Buy/Sell £165.99 53.79%
NOVN Stock Forecast Novartis Outperform 10
CHF88.80 Buy/Sell CHF105.00 23.95%
PFE Stock Forecast Pfizer Outperform 2
$28.37 Buy/Sell $32.87 10.82%

TTY Biopharm Company Revenue Forecast for 2023 - 2025 - 2030

In the last two years, TTY Biopharm Company's Revenue has grown, increasing from NT$4.22B to NT$5.06B – an increase of 19.89%. For next year, the 2 analysts predict Revenue of NT$5.74B, which would mean an increase of 13.45%. Over the next seven years, the pros' prediction is Revenueof NT$5.77B, which would mean a seven-year growth forecast of 13.91%.

2024 Rev Forecast
NT$5.74B
2025 Rev Forecast
NT$6.30B
2026 Rev Forecast
NT$5.65B
2027 Rev Forecast
NT$5.48B
2028 Rev Forecast
NT$5.58B
2029 Rev Forecast
NT$5.82B
2030 Rev Forecast
NT$5.77B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
SAN Stock Forecast Sanofi Outperform 16
88.32€ Buy/Sell 102.80€ 21.15%
CSL Stock Forecast CSL Outperform 12
$281.20 Buy/Sell $205.51 -27.94%
GSK Stock Forecast GSK Outperform 12
£16.75 Buy/Sell £17.30 11.04%

TTY Biopharm Company Dividend per Share Forecast for 2023 - 2025 - 2030

In the last two years, TTY Biopharm Company has seen a decline in its Dividend per Share, from NT$4.00 to NT$3.40 – a 15.00% decrease. In the next year, analysts expect Dividend per Share to reach NT$4.10 – an increase of 20.59%. For the next seven years, the forecast is for Dividend per Share to grow by 13.62%.

2024 DPS Forecast
NT$4.10
2025 DPS Forecast
NT$4.16
2026 DPS Forecast
NT$3.74
2027 DPS Forecast
NT$3.65
2028 DPS Forecast
NT$3.80
2029 DPS Forecast
NT$3.92
2030 DPS Forecast
NT$3.86
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAX Stock Forecast Baxter International Inc Outperform 17
$43.48 Buy/Sell $44.86 3.50%
1093 Stock Forecast CSPC Pharmaceutical Group Outperform 18
HK$6.01 Buy/Sell HK$9.50 54.24%
4142 Stock Forecast Adimmune - 10
NT$31.05 Buy/Sell NT$55.00 -100.00%

TTY Biopharm Company Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
NT$1.10B

TTY Biopharm Company EBITDA Forecast for 2023 - 2025 - 2030

In the last two years, TTY Biopharm Company's EBITDA has grown by 26.76%, from NT$1.11B to NT$1.41B. For the next year, analysts are expecting EBITDA to reach NT$1.87B – an increase of 32.89%. Over the next seven years, experts predict that EBITDA will grow by 27.49%.

2024 EBITDA Forecast
NT$1.87B
2025 EBITDA Forecast
NT$2.00B
2026 EBITDA Forecast
NT$1.74B
2027 EBITDA Forecast
NT$1.65B
2028 EBITDA Forecast
NT$1.73B
2029 EBITDA Forecast
NT$1.82B
2030 EBITDA Forecast
NT$1.80B

TTY Biopharm Company EBIT Forecast for 2023 - 2025 - 2030

In the last two years, TTY Biopharm Company's EBIT has grown from NT$957.38M to NT$1.23B – a 28.26% increase. Next year, analysts are expecting EBIT to reach NT$1.62B – an increase of 31.52%. Over the next seven years, the forecast is for EBIT to grow by 35.04%.

2024 EBIT Forecast
NT$1.62B
2025 EBIT Forecast
NT$1.92B
2026 EBIT Forecast
NT$1.62B
2027 EBIT Forecast
NT$1.50B
2028 EBIT Forecast
NT$1.56B
2029 EBIT Forecast
NT$1.67B
2030 EBIT Forecast
NT$1.66B

TTY Biopharm Company EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, TTY Biopharm Company's EPS has decreased from NT$3.71 to NT$0.00 – a 100.00% drop! For next year, the 2 analysts predict EPS of NT$5.72, which would mean an increase of 100.00%. Over the next seven years, the pros' prediction is EPSof NT$5.98, which would mean a seven-year growth forecast of 100.00%.

2024 EPS Forecast
NT$5.72
2025 EPS Forecast
NT$6.67
2026 EPS Forecast
NT$6.35
2027 EPS Forecast
NT$4.04
2028 EPS Forecast
NT$4.69
2029 EPS Forecast
NT$5.44
2030 EPS Forecast
NT$5.98